Exabis Library
Welcome to the e-CCO Library!
P499: A comparison of health-related quality of life in nurse-led vs. conventional inflammatory bowel disease follow-up
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P499: Accessing ultrasonographic transmural healing in patients with Crohn’s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels?
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P499: Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P499: Exclusive enteral nutrition induces transmural healing in adults with active Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P499: Long-term outcomes of infliximab and predictors of response in 213 patients with ulcerative colitis: a hospital-based cohort study from Korea
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P499: Sexual dysfunction is frequent among inflammatory bowel disease patients: results of a prospective study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P499: Use of an Inflammatory Bowel Disease illustrated guide as a patient education tool
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P500: Assessing physical activity, fatigue and quality of life in an outpatient cohort of IBD patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P500: Capsule endoscopy reveals small intestinal mucosal Crohn’s disease healing after treatment with adalimumab: preliminary results of the SIMCHA study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P500: Effectiveness and safety in Crohn's disease patients who were treated with CT-P13
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P500: Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P500: Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P500: The effects of EBV naïve status on treatment decisions in patients with inflammatory bowel disease: Does the risk of GI lymphoma justify the cost?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P500: The use of budesonide results in lower risk for infections compared to systemic glucocorticoids
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P501 Thiopurine withdrawal in patients with Crohn’s disease: the SURESTE study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P501: Abdominal obesity in Paediatric Crohn’s disease is associated with adipokine dysregulation
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P501: Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P501: High TNF-production of CD14+ cells and short disease duration are independent predictive factors for response to Infliximab treatment
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P501: Incidence and therapeutic management/treatment of very early onset inflammatory bowel disease during 2015-2020.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM